.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a median follow-up of 11 months, individuals with metastatic stomach lumps that got biomarker-matched therapies based upon flowing cyst DNA profiling presented a higher professional perk than those obtaining incomparable therapy.